Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more
Market Cap & Net Worth: Enlivex Therapeutics Ltd (ENLV)
Enlivex Therapeutics Ltd (NASDAQ:ENLV) has a market capitalization of $261.12 Million ($261.12 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25711 globally and #8749 in its home market, demonstrating a -5.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enlivex Therapeutics Ltd's stock price $1.10 by its total outstanding shares 237381498 (237.38 Million).
Enlivex Therapeutics Ltd Market Cap History: 2015 to 2026
Enlivex Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $36.75 Billion to $261.12 Million (-39.34% CAGR).
Index Memberships
Enlivex Therapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #685 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2214 of 3165 |
Weight: Enlivex Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Enlivex Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enlivex Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
878.84x
Enlivex Therapeutics Ltd's market cap is 878.84 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.00 Billion | $2.28 Million | -$11.82 Million | 878.84x | N/A |
Competitor Companies of ENLV by Market Capitalization
Companies near Enlivex Therapeutics Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Enlivex Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Enlivex Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Enlivex Therapeutics Ltd's market cap moved from $36.75 Billion to $ 261.12 Million, with a yearly change of -39.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $261.12 Million | +56.43% |
| 2025 | $166.93 Million | -39.90% |
| 2024 | $277.74 Million | -56.67% |
| 2023 | $640.93 Million | -31.44% |
| 2022 | $934.81 Million | -36.99% |
| 2021 | $1.48 Billion | -25.86% |
| 2020 | $2.00 Billion | +0.46% |
| 2019 | $1.99 Billion | +35.51% |
| 2018 | $1.47 Billion | -66.14% |
| 2017 | $4.34 Billion | -56.04% |
| 2016 | $9.88 Billion | -73.13% |
| 2015 | $36.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Enlivex Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $261.12 Million USD |
| MoneyControl | $261.12 Million USD |
| MarketWatch | $261.12 Million USD |
| marketcap.company | $261.12 Million USD |
| Reuters | $261.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.